Atherothrombotic events and clopidogrel therapy.
Guirguis
Micheal
M
D000368:Aged; D000077144:Clopidogrel; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics* / Q000378:metabolism; D004347:Drug Interactions; D017700:Embolism, Cholesterol / Q000139:chemically induced*; D004791:Enzyme Inhibitors / Q000009:adverse effects; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000378:metabolism; D011110:Polymorphism, Genetic; D012307:Risk Factors; D013927:Thrombosis / Q000139:chemically induced*; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000378:metabolism
D065607:Cytochrome P-450 Enzyme Inhibitors; D004791:Enzyme Inhibitors; D010975:Platelet Aggregation Inhibitors; D003577:Cytochrome P-450 Enzyme System; D000077144:Clopidogrel; C510164:CYP3A5 protein, human; D051544:Cytochrome P-450 CYP3A; D013988:Ticlopidine